<DOC>
	<DOCNO>NCT00589381</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fenretinide Lym-X-Sorb™ , work different way stop growth cancer cell , either kill cell stop dividing . PURPOSE : This phase I trial study side effect best dose fenretinide Lym-X-Sorb™ treating patient recurrent resistant solid tumor lymphoma .</brief_summary>
	<brief_title>Fenretinide Lym-X-Sorb™ Treating Patients With Recurrent Resistant Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose fenretinide Lym-X-Sorb™ oral powder ( 4-HPR/LXS oral powder ) patient recurrent and/or resistant solid tumor lymphomas . - To define toxicity 4-HPR/LXS oral powder patient . - To determine plasma pharmacokinetics 4-HPR/LXS oral powder patient . Secondary - To determine level fenretinide deliver 4-HPR/LXS oral powder normal peripheral blood mononuclear cell . OUTLINE : This multicenter study . Patients receive oral fenretinide Lym-X-Sorb™ oral powder ( 4-HPR/LXS oral powder ) ( mixed food carrier ) three time daily day 1-7 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients achieve stable disease response well may receive additional course treatment discretion treat physician principal investigator . Blood sample collect periodically pharmacokinetic pharmacodynamic study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ( NIH pathology department ) diagnosis 1 following : Solid tumor malignancy metastatic unresectable Lymphoma standard treatment curative measure exist , associate minimal patient survival benefit Recurrent and/or resistant disease Measurable evaluable disease No known brain metastases Patients whose brain metastatic disease status remain stable ≥ 3 month treatment may eligible discretion principal investigator ( without steroid antiseizure medication ) PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy ≥ 3 month Absolute neutrophil count ≥ 1,500/µL Platelets ≥ 100,000/µL ( CTCAE v.3 grade 1 thrombocytopenia allow explain involvement bone marrow lymphoma ) Total bilirubin ≤ 1.5 time normal institutional limit ( 2.5 mg/dL patient Gilbert 's syndrome ) AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 time upper limit normal ( ULN ) Creatinine &lt; 1.5 time ULN OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use two method birth control , include least one highly effective method ( e.g. , intrauterine device [ IUD ] , hormonal birth control pills/injections/implants , tubal ligation partner 's vasectomy ) , one additional effective method ( e.g. , latex condom , diaphragm , cervical cap ) , prior , , 2 month completion study treatment Men must use latex condom every time sexual intercourse therapy 2 month discontinue fenretinide , even successful vasectomy No clinically significant illness could compromise participation study , include , limited , follow : Active uncontrolled infection Immune deficiency confirm diagnosis HIV infection Uncontrolled diabetes Uncontrolled hypertension Symptomatic congestive heart failure Unstable angina pectoris Myocardial infarction within past 6 month Uncontrolled cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement No known wheat gluten allergy allergy sensitivity study drug No history pancreatitis evidence elevated amylase lipase ≥ grade 2 accompany symptom pancreatitis ( e.g. , abdominal pain ) PRIOR CONCURRENT THERAPY : Recovered adverse event and/or toxicity due prior chemotherapy biologic therapy No chemotherapy biologic therapy within 4 week prior enter study ( 6 week nitrosoureas , mitomycin C , UCN01 ) At least 1 month since prior radiotherapy major surgery At least 2 week since prior administration study drug exploratory IND/phase 0 study Patients receive bisphosphonates cancer undergo androgen deprivation therapy prostate cancer eligible therapy No concurrent sulfonamides No concurrent investigational agent No concurrent cancer chemotherapy , immunomodulating agent ( include systemic corticosteroid ) Patients must take drug suspect cause pseudo tumor cerebri , include follow : Tetracycline Nalidixic acid Nitrofurantoin Phenytoin Sulfonamides Lithium Amiodarone Vitamin A ( except part routine total parenteral nutrition vitamin supplement single daily standard dose oral multivitamin supplement ) No concurrent herbal supplement alternative therapy medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>